Switzerland has 151 researchers on Clarivate’s 2026 list of Highly Cited Researchers — up from 130 a year earlier, and enough to lift the country from ninth to eighth place worldwide.
The annual list, compiled by the British-American data and analytics firm Clarivate, identifies scientists whose papers are cited unusually often by other researchers. This year’s edition covers nearly 7,000 scientists from 62 countries — 7,090 awards in total, which Clarivate describes as the top 0.1 percent of the most-cited researchers.
Switzerland’s 151 nods amount to 2.1 percent of all awards worldwide. The count spans every discipline, not just medicine.
In the health fields, the pattern is striking: an outsized share of this year’s citation leaders work in immunology, neuroscience and oncology, and many cross disciplinary lines. That matters because citation counts shape how universities, funders and governments judge research strength — even though, as the source notes, they measure attention, not quality.
The University of Basel reports 13 representatives on this year’s list. Oncologist Alfred Zippelius appears in the immunology category. So does neurologist Ludwig Kappos, internationally known for his research on multiple sclerosis.
The “Cross-Field” category, reserved for researchers cited heavily across several disciplines, includes Alzheimer’s researcher Anne Eckert and breast surgeon Walter P. Weber. Several Biozentrum researchers made the cut as well, among them Torsten Schwede in biology and biochemistry.
Clarivate draws on its Web of Science Core Collection database. For the 2026 edition, it analyzed publications from the eleven years between 2015 and 2025.
The core requirement: papers that rank among the most-cited 1 percent in their field and publication year. Researchers need several such papers to qualify, alongside citation counts and field-specific thresholds. The evaluation runs across 21 subject areas, with Cross-Field as the catch-all for interdisciplinary work.
The firm also screens for suspicious patterns — excessive self-citation, unusually high publication counts and possible manipulation — using both statistical methods and qualitative review by specialists.
The list is popular for benchmarking institutions, but its limits are real. Heavy citation shows that a paper is widely noticed in the field; it does not directly show whether the results are original, methodologically sound or clinically relevant.
For Switzerland’s biomedical community, the 2026 edition still reads as a good year: more awards, a higher country rank, and Basel names — Zippelius, Kappos, Eckert, Weber, Schwede — carrying the flag in the fields where global attention concentrates, according to medinside.